APA (7th ed.) Citation

BS, K., M, G., T, U., XH, G., AH, P., M, M., . . . S, W. (2026). Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials. American journal of clinical dermatology, 27(1), 167. https://doi.org/10.1007/s40257-025-00993-1

Chicago Style (17th ed.) Citation

BS, Kim, Gonçalo M, Ugajin T, Gao XH, Praestgaard AH, Makhija M, Zahn J, Bansal A, and Wiggins S. "Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials." American Journal of Clinical Dermatology 27, no. 1 (2026): 167. https://doi.org/10.1007/s40257-025-00993-1.

MLA (9th ed.) Citation

BS, Kim, et al. "Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials." American Journal of Clinical Dermatology, vol. 27, no. 1, 2026, p. 167, https://doi.org/10.1007/s40257-025-00993-1.